Novel polymethoxylated chalcones as potential compounds against kras-mutant colorectal cancers
Abstract
Background/Objective: KRAS-mutant colorectal cancers (CRC) are tumors that are associated with poor prognosis. However, no effective treatments are available to target them. Therefore, we designed and synthesized novel chalcone analogs, small organic molecules, to investigate their effects on KRAS-mutant CRC cells.
Methods: Fourteen new chalcone analogs were synthesized, optimized, characterized, and tested against two KRAS-mutant CRC cell lines (HCT-116 and LoVo), one p-53 and BRAF mutant CRC cell line (HT-29) and one normal immortalized colon cells (NCE-1 E6/E7). Effects on cell viability, apoptosis, cell cycle, migration, colony formation, EMT, and angiogenesis were investigated.
Results: Compounds 3 and 14 were the most effective. Compound 3 showed potent activity against HCT-116 and LoVo cell lines (GI50 of 6.10 μM and 7.00 μM, respectively). While compound 14 showed GI50 of 8.60 μM and 8.80 μM on HCT-116 and LoVo cell lines, respectively. Both compounds were approximately 2-3 times more selective toward cancer cells rather than normal colon cells. Compound 3 was effective in inducing apoptosis in HCT-116 cells via Bax upregulation and Bcl-2 downregulation. Invasion and metastasis of KRAS-mutant cells were modulated by compounds 3 and 14 through significant inhibition of cell migration and the prevention of colony formation. In addition, they reversed EMT by downregulation of EMT markers (vimentin, fascin, and β- catenin) and upregulation of cell-cell adhesion marker, E-cadherin. Furthermore, compounds 3 and 14 had significantly inhibited angiogenesis in ovo.
Conclusion: Compounds 3 and 14 represent potent and selective leads for KRAS-mutant CRC cells, thus, further in vitro and in vivo studies are necessary to confirm their effect on KRAS-mutant CRCs.
Collections
- Biomedical Research Center Research [735 items ]
- Medicine Research [1448 items ]
- Pharmacy Research [1280 items ]
Related items
Showing items related by title, author, creator and subject.
-
Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer
Elkhalifa, Dana; Siddique, Abu Bakar; Qusa, Mohammed; Cyprian, Farhan S.; El Sayed, Khalid; Alali, Feras; Al Moustafa, Ala-Eddin; Khalil, Ashraf... more authors ... less authors ( Elsevier Masson s.r.l. , 2020 , Article)Great strides have been made in triple negative breast cancer (TNBC) treatment, which represents 20% of total predicted annual US breast cancer (BC) cases. Despite the development of several therapeutics, TNBC patients ... -
Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors
Hammuda, Arwa; Shalaby, Raed; Rovida, Stefano; Edmondson, Dale E.; Binda, Claudi; Khalil, Ashraf... more authors ... less authors ( Elsevier Masson SAS , 2016 , Article)A novel series of substituted chalcones were designed and synthesized to be evaluated as selective human MAO-B inhibitors. A combination of either methylsulfonyl or trifluoromethyl substituents on the aromatic ketone moiety ... -
The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
Shraim B.A.; Moursi M.O.; Benter I.F.; Habib A.M.; Akhtar S. ( Frontiers Media S.A. , 2021 , Article)Diabetes mellitus is a major debilitating disease whose global incidence is progressively increasing with currently over 463 million adult sufferers and this figure will likely reach over 700 million by the year 2045. It ...